title: Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients.
abstract: BACKGROUND
  In Western countries, only a small proportion of patients with hepatocellular carcinoma (HCC) can be treated with surgical resection. For other patients, locoregional management by transcatheter oily chemoembolization seems to be useful and warrants evaluation.
  
  
  METHODS
  One hundred and twenty-seven French patients with an inoperable HCC were treated by transcatheter oily chemoembolization. The efficiency of the treatment was assessed by a comparison of this group with a group of 127 untreated patients. Each patient of the treated group was matched closely with an untreated patient for all the main clinical, anatomic, and biologic features that characterize the spontaneous evolution of HCC.
  
  
  RESULTS
  The overall probabilities of survival in the treated group were 64%, 38%, 27%, and 27% at 1, 2, 3, and 4 years, respectively; those for the untreated group were 18%, 6%, and 5% at 1, 2 and 3 years, respectively (P < 0.0001). The survival was significantly increased in patients with Okuda Stage I and II disease (P < 0.0001), but not in those with Stage III. Karnofsky and Child-Pugh scores remained stable during the follow-up period and dropped only shortly before patients died.
  
  
  CONCLUSIONS
  Transcatheter oily chemoembolization is an efficient treatment for unresectable HCC for the palliation of symptoms as well as for the prolongation of survival with a good quality of life.
authors.affiliation: Services d'Hépatogastroentérologie et de Chirurgie, Centre Hospitalier Universitaire, Strasbourg, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Bronowicki
authors.forename: D
authors.initials: D
authors.lastname: Vetter
authors.forename: F
authors.initials: F
authors.lastname: Dumas
authors.forename: K
authors.initials: K
authors.lastname: Boudjema
authors.forename: R
authors.initials: R
authors.lastname: Bader
authors.forename: A M
authors.initials: AM
authors.lastname: Weiss
authors.forename: J J
authors.initials: JJ
authors.lastname: Wenger
authors.forename: P
authors.initials: P
authors.lastname: Boissel
authors.forename: M A
authors.initials: MA
authors.lastname: Bigard
authors.forename: M
authors.initials: M
authors.lastname: Doffoel
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000401:mortality / Q000628:therapy*; D002423:Cause of Death; D016461:Chemoembolization, Therapeutic / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005602:France; D006499:Hepatic Artery / Q000187:drug effects; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000509:alpha-Fetoproteins; D015251:Epirubicin; D007459:Iodized Oil; D004317:Doxorubicin; D002945:Cisplatin